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Introduction
Older people have the highest prevalence rates of 
polypharmacy, inappropriate prescribing and 
adverse drug reactions (ADRs) with associated 
high levels of morbidity [Permpongkosol, 2011; 
Scott and Jayathissa, 2010]. Studies from several 
European countries consistently show about 6% 
of all hospital admissions in adults can be directly 
attributed to ADRs [Pirmohamed, 2004; 
Franceschi et  al. 2008; Hamilton et  al. 2011]. 
Another large study in the Netherlands calcu-
lated that €94 million (0.5%) of the country’s 
total hospital budget was spent on medication-
related admissions [Leendertse et al. 2011]. The 
cost for the UK was estimated around €706 
million in 2004 [Pirmohamed et al. 2004] and 
€434 million in Germany in 2006 [Rottenkolber 
et  al. 2011]. There is wide agreement that the 
best strategy to prevent ADR-related morbidity 
is to focus on high-risk groups such as older peo-
ple with polypharmacy [Leendertse et  al. 2011; 
Dequito et  al. 2011]. Demand for geriatricians 
and other specialists in this field far outweigh 
supply, so the prospect of easy-to-use software to 
guide clinicians has tremendous potential to 
improve patient care. However, a major chal-
lenge is that any software solutions would need 
to safely handle the complexity that characterizes 
this patient group. A recent review concluded 
that there are no validated, reliable, widely used 
prevention strategies in older people [Petrovic 
et al. 2012]. Although there are a number of well-
known existing tools such as the STOPP-START 
criteria [O’Mahony et al. 2015] and Beers criteria 
[American Geriatrics Society 2015 Beers Criteria 
Update Expert Panel, 2015], they are usually 
limited to use in research and are not easily 
applied in routine clinical practice due to the vol-
ume of information and multiple rules that apply 
[Caslake et al. 2013]. Some interventions provide 
a structured format for the review of prescribed 
medication, but either rely on the clinician’s con-
siderable specialist clinical pharmacology knowl-
edge in older people or involve applying one of 
the above tools [e.g. the systematic tool to reduce 
inappropriate prescribing (STRIP)] [Keisjers 
et al. 2014]. A number of Computerized Provider 
Order Entry (CPOE) systems are in use for elec-
tronic prescribing, but none are specially designed 
for older people and, though partly effective, they 
rely mostly on warning clinicians only about 
drug–drug interactions [Schiff et  al. 2015]. 
Moreover, another potentially important strategy 
to avoid ADRs involves maximizing use of evi-
dence-based nonpharmacological therapies but 
none of the above tools address this. Therefore, 
there was a clear need to develop and validate a 
new and more sophisticated tool that could 
address this important gap. Here, we describe 
the efforts made to date by our group to develop 
and test a new software engine for the optimiza-
tion of medical and nondrug therapy in older 
people with multimorbidity and polypharmacy 
(SENATOR).
Establishing the SENATOR consortium
The SENATOR consortium is an international 
collaboration funded under the European Union 
FP7 programme (http://www.senator-project.eu). 
This followed a call for investigator-driven pro-
jects to address management of elderly individuals 
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with multiple diseases. It is led by Professor Denis 
O’Mahony in University College Cork and 
includes collaborators from 12 European organi-
zations with a wide range of expertise including 
geriatric medicine, clinical pharmacology, soft-
ware design and project management.
SENATOR software
The SENATOR software incorporates a number 
of individually validated tools to provide clini-
cians with evidence-based recommendations. 
Key components include the START-STOPP2 
criteria [O’Mahony et al. 2015] and databases of 
licensed indications for medications and drug–
drug interactions (from the British National 
Formulary and a licensed CPOE product called 
SafeScript). The risk of death in the next year is 
calculated using CIRS-G (Cumulative Illness 
Rating Scale for Geriatrics) [Miller et al. 1992]. 
Another novel component is a tool that predicts 
the risk of an ADR, since this may influence the 
extent of deprescribing. Since the best current 
tools, such as GerontoNet [Onder et al. 2010], 
have only moderate ability to predict ADRs in 
older people [Petrovic et  al. 2012], the study 
team plan to create, test and validate its own 
bespoke tool from the extensive clinical data that 
was being collected for the study. This will only 
be incorporated into the final product if it is 
superior to GerontoNet when validated. 
Provided the software is given enough informa-
tion on the patient’s medical history and usual 
medications, it can make recommendations on 
inappropriate prescribing. This includes address-
ing under-prescribing of evidence-based treat-
ments and recommendations for medication 
withdrawal to combat polypharmacy. To help 
keep prescribing costs down, SENATOR has 
information on drug availability, pricing and pol-
icies for each participating centre, and can make 
recommendations on the most cost-effective 
option. The latter involved a significant amount 
of original development work as this information 
is not easily available. The SENATOR soft-
ware’s output is in the form of easy to follow 
bullet-point recommendations. They will still 
require clinicians to make their own, final judg-
ment in conjunction with the patient themselves, 
as there are a number of factors that the software 
cannot easily take into account. In particular, 
there is no way of taking into account patient 
preference, or the result of any previous attempts 
at medical optimisation.
Nondrug therapies
One of the most exciting and innovative aspects 
of the SENATOR project is the development of 
individually tailored advice on appropriate non-
pharmacological therapies. This aspect has 
required considerable original research and devel-
opment as there are no existing compendia of 
nonpharmacological therapies, along with their 
evidence-based indications. This is in stark con-
trast to pharmacological therapies, where regu-
larly updated tomes, such as the British National 
Formulary, provide clinicians with all of the infor-
mation they need for safe prescribing in an easily 
accessible format. It is therefore perhaps unsur-
prising that nondrug therapies are currently 
under-utilized [Chen et  al. 2014; Naci and 
Ioannidis, 2013].
The SENATOR project developed a bespoke 
methodology to gather the best available evidence 
called Optimal Non-drug Therapy for Older 
Persons (ONTOP; for a detailed description see 
Abraha et al. [2015a]). Initially, common geriatric 
conditions that may respond to nondrug therapy 
were selected for inclusion by panel discussion 
involving all the principal SENATOR investiga-
tors (authors). For each one, an international 
panel of 13 experts were asked to list and rate the 
clinical importance of all available outcome meas-
ures with the aim of identifying critically impor-
tant outcome measures using a Delphi technique. 
For example, for the management of pressure 
ulcers, rates of complete wound healing was rated 
as a critically important outcome measure, 
whereas length of hospital stay was not. The next 
stage involved a ‘systematic review of systematic 
reviews’ of each condition, without specifying any 
individual interventions. This was important to 
avoid missing any little-known interventions. 
Reports were included if they assessed any non-
drug therapy using systematic review methodol-
ogy. From included reviews, all relevant primary 
studies were identified for inclusion in the final 
analysis. Usual inclusion criteria included: mean 
study population age over 65 years, randomized 
controlled trial design and outcomes measures 
that included at least one rated as critically impor-
tant by the Delphi panel. This allowed the team to 
generate specific questions using Population, 
Intervention, Comparator, Outcomes (PICO) 
methodology to evaluate the evidence base of each 
intervention for each condition, and in specific 
patient groups. Meta-analyses were used where 
appropriate. Finally, results of each meta-analysis 
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and systematic review are evaluated for quality 
using the GRADE methodology [Guyatt et  al. 
2011]. Bullet-form recommendations for inclu-
sion in the SENATOR software are written where 
there is at least moderate evidence of effect. These 
recommendations can potentially be individual-
ized for patients by the software (e.g. a recom-
mendation for group exercise therapy may only be 
triggered where incontinence is listed as a prob-
lem, and the patient is female).
The initial SENATOR trial includes a ‘proof of 
concept’ study testing the feasibility of making 
computer-generated recommendations on non-
pharmacological therapy. Initially, the trial will 
evaluate whether clinical teams follow advice 
on the prevention of delirium using nondrug 
techniques. The final SENATOR software will 
include recommendations on the nondrug treat-
ment or prevention of 10 common geriatric con-
ditions and some of the ONTOP reviews are 
already available (see Table 1) [Abraha et  al. 
2015b, 2016; Lozano-Montoya et  al. 2016; 
Vélez-Díaz-Pallarés et  al. 2015, 2016; Rimland 
et al. 2016].
Pan-European tool
One of the remits of the project was that any tool 
that was developed would be suitable for use 
throughout Europe. This represents a major 
challenge, as healthcare systems, therapy availa-
bility and practices vary widely. Moreover, there 
are significant language barriers. A major work 
package was devised to translate and reverse-
translate all of the SENATOR user interfaces 
and recommendations from English to Spanish, 
French, Italian and Icelandic to cover the native 
language of all of the countries that would test 
the software in a clinical trial.
Testing the software
One of the major goals of SENATOR is to 
reduce ADR, so the rate of ADR was the obvious 
primary outcome for a randomized controlled 
trial. Although SENATOR is designed to be 
used in any setting, a decision was made to test 
it in the hospitalized setting first as this allowed 
more pragmatic recruitment of large numbers of 
volunteers at high risk of ADR within a short 
time period. Trials of interventions to reduce 
ADR pose several challenges. It is impossible to 
achieve effective and safe blinding of clinicians 
and patients. There is a risk of contamination of 
the control group due to clinicians learning from 
the intervention. Although these risks can be 
mitigated with a cluster-randomized design, the 
latter also poses many challenges. The underly-
ing risk of ADR in different ward areas varies 
widely, so many different clusters would be 
needed to avoid an inherent bias in one arm just 
by chance. Moreover, out of hours cross-cover 
arrangements and the high workplace mobility 
of trainee medical staff between control and 
intervention units would mean the risk of con-
tamination across clusters remained. In addi-
tion, the danger of ascertainment bias is high as 
ADRs in older people can easily be missed or 
dismissed.
In an attempt to overcome many of these inherent 
difficulties, the SENATOR trial was divided into 
two distinct trial periods. The first was an obser-
vational study across hospitals in six different 
countries. This allowed verification of recruit-
ment rate and baseline ADR rate across each 
country and within each region in different types 
of wards. It also allowed the development and 
testing of the SENATOR software interface, a 
tool to predict ADR and the feasibility of data col-
lection for all the SENATOR components ahead 
of the trial in Period 2. The randomized con-
trolled trial (Period 2) will start in 2016 and will 
be an unblinded controlled trial with randomiza-
tion at the level of the patient. Important second-
ary outcome measures include quality of life, 
length of stay in hospital, mortality and health-
care utilization costs both during the admission 
and at 3-month follow up.
Table 1. Planned list of conditions that the SENATOR 
software will advise on ONTOP.
Condition
Delirium
Dementia
Falls
Heart failure
Immobility
Orthostatic hypotension
Pressure sores
Stroke
Undernutrition
Urinary incontinence
ONTOP, Optimal Non-drug Therapy for Older Persons.
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Dissemination
The trial protocol is publicly available 
[ClinicalTrials.gov identifier: NCT02097654] 
and all major findings will be presented widely at 
international conferences and published in major 
scientific journals. Results of the main trial should 
become available late in 2018. If successful, 
SENATOR will be an extremely useful adjunct to 
any clinician working with older people.
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